Deep Dive: Deep Dive Into RBX2660

The FDA approved RBX2660 for the prevention of recurrent CDI last week, making it the first ever approved live microbiota therapeutic. Dr. Sahil Khanna was an investigator on the PUNCH CD3 study testing the product and spoke about the excitement of the drug and why it might result in a significant reduction in C difficile cases in the coming years.